|
||
|
Press ReleaseAccuro Biologics Ltd enters into a collaborative agreement with Areta International s.r.l.ABERDEEN, UK -- April 23, 2008 -- Accuro Biologics Ltd, a privately held biotechnology services company, and Areta International, (Gerenzano, Italy), a GMP certified service company with expertise in process development and manufacture of recombinant protein therapeutics, announce the execution of a three year service agreement. Through the terms of the agreement, Accuro Biologics will provide expertise to Areta in antibody engineering, expression clone development and immunogenicity profiling. The Agreement allows Accuro access to antibody development services, scale-up technologies and other Areta GMP portfolio services including process development and manufacturing. The terms of the deal were not disclosed. “This agreement enhances the existing core competences of the two companies and provides our clients the opportunity to access a unique and rich portfolio of antibody and protein development services. The flexibility and project focussed strategy of Areta, together with their strong track-record and fully accredited quality management procedures, fit well with our own service ethos” said Graham Carter Managing Director of Accuro Biologics. “The excellent antibody and protein engineering capabilities of Accuro Biologics make them an ideal partner to complement the strong portfolio services already provided by Areta International” said Dr. Maria Luisa Nolli CEO, Areta International. For more information, please contact: Graham Carter Tel: +44 (0)1224 707337 About Areta InternationalAreta International is a biotech company focused on the tailor-made supply of cells for cell therapy, antibodies and recombinant proteins for the development of biodrugs. The company is ISO 9001 certified and obtained GMP certification in 2004 GMP. Areta was founded in 1999 by Dr Maria Luisa Nolli, the company is privately owned and located in Gerenzano in the outskirts of Milan, Italy. For further information, please contact: Dr. Maria Luisa Nolli, CEO Tel: +39 02 96489264 Return to Press Releases |
||
Printer Friendly